Previous Section
Drug Therapy
1. Trastuzumab not for ductal carcinoma in situ?
- Author
- Nahleh Z; Namakydoust A; Bakkar R; Bishop J;
- Institution
- Karmanos Cancer Institute/Wayne State University, Detroit, Michigan ,College of Medicine, Department of Pathology, University of Cincinnati, Cincinnati, Ohio, USA.
- Journal
- Anticancer Drugs. 2007 Nov;18(10):1231-5.
- Abstract URL
- Click here to view abstract
2. Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma.
- Author
- Jones RL; Lakhani SR; Ring AE; Ashley S; Walsh G; Smith IE;
- Institution
- Breast Unit, Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK, and Molecular and Cellular Pathology, School of Medicine, University of Queensland, Mayne Medical School, Herston, Australia.
- Journal
- Br J Cancer. 2006 Feb 13;94(3):358-62.
- Abstract URL
- Click here to view abstract
3. Impact of estrogen receptor expression and other clinicopathologic features on tamoxifen use in ductal carcinoma in situ.
- Author
- Hird RB; Chang A; Cimmino V; Diehl K; Sabel M; Kleer C; Helvie M; Schott A; Young J; Hayes D; Newman L;
- Institution
- Division of Surgical Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA.
- Journal
- Cancer. 2006 May 15;106(10):2113-8.
- Abstract URL
- Click here to view abstract
4. Tamoxifen use in patients with ductal carcinoma in situ and T1a/b N0 invasive carcinoma.
- Author
- Nakhlis F; Lazarus L; Hou N; Acharya S; Khan SA; Staradub VL; Rademaker AW; Morrow M; Nakhlis F; Lazarus L; Hou N; Acharya S; Khan SA; Staradub VL; Rademaker AW; Morrow M;
- Institution
- Department of Surgery, Lynn Sage Breast Program, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
- Journal
- J Am Coll Surg. 2005 Nov;201(5):688-94. Epub 2005 Aug 31.
- Abstract URL
- Click here to view abstract
Next: Surgical Therapy
